Skip to main content
Erschienen in: Osteoporosis International 3/2008

01.03.2008 | Review

Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis

verfasst von: P. Vestergaard, N. R. Jorgensen, P. Schwarz, L. Mosekilde

Erschienen in: Osteoporosis International | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Summary

Fluoride has fallen into discredit due to the absence of an anti-fracture effect. However, in this meta-analysis, a fracture reducing potential was seen at low fluoride doses [≤20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride)]: OR = 0.3, 95% CI: 0.1–0.9 for vertebral and OR = 0.5, 95% CI: 0.3–0.8 for non-vertebral fractures.

Introduction

Fluoride is incorporated into bone mineral and has an anabolic effect. However, the biomechanical competence of the newly formed bone may be reduced.

Methods

A systematic search of PubMed, Embase, and ISI web of science yielded 2,028 references.

Results

Twenty-five eligible studies were identified. Spine BMD increased 7.9%, 95% CI: 5.4–10.5%, and hip BMD 2.1%, 95% CI: 0.9–3.4%. A meta-regression showed increasing spine BMD with increasing treatment duration (5.04 ± 2.16%/year of treatment). Overall there was no significant effect on the risk of vertebral (OR = 0.8, 95% CI: 0.5–1.5) or non-vertebral fracture (OR = 0.8, 95% CI: 0.5–1.4). With a daily dose of ≤20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride), there was a statistically significant reduction in vertebral (OR = 0.3, 95% CI: 0.1–0.9) and non-vertebral (OR = 0.5, 95% CI: 0.3–0.8) fracture risk. With a daily dose >20 mg fluoride equivalents, there was no significant reduction in vertebral (OR = 1.3, 95% CI: 0.8–2.0) and non-vertebral (OR = 1.5, 95% CI: 0.8–2.8) fracture risk.

Conclusions

Fluoride treatment increases spine and hip BMD, depending on treatment duration. Overall there was no effect on hip or spine fracture risk. However, in subgroup analyses a low fluoride dose (≤20 mg/day of fluoride equivalents) was associated with a significant reduction in fracture risk.
Literatur
1.
Zurück zum Zitat Haguenauer D, Welch V, Shea B et al (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727–738PubMedCrossRef Haguenauer D, Welch V, Shea B et al (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727–738PubMedCrossRef
2.
Zurück zum Zitat Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef
3.
Zurück zum Zitat Posner AS (1996) The effect of fluoride on bone mineralisation. In: Fejerskov O, Ekstrand J, Burt BA (eds) Fluoride in dentistry, 1st edn. Munksgaard, Copenhagen, pp 88–96 Posner AS (1996) The effect of fluoride on bone mineralisation. In: Fejerskov O, Ekstrand J, Burt BA (eds) Fluoride in dentistry, 1st edn. Munksgaard, Copenhagen, pp 88–96
4.
Zurück zum Zitat Qu H, Wie M (2006) The effect of fluoride contents in fluoridated hydroxyapatite on osteoblast behavior. Acta Biomater 2:113–119PubMedCrossRef Qu H, Wie M (2006) The effect of fluoride contents in fluoridated hydroxyapatite on osteoblast behavior. Acta Biomater 2:113–119PubMedCrossRef
5.
Zurück zum Zitat Kassem M, Mosekilde L, Eriksen EF (1994) Effects of fluoride on human bone cells in vitro: differences in responsiveness between stromal osteoblast precursors and mature osteoblasts. Eur J Endocrinol 130:381–386PubMed Kassem M, Mosekilde L, Eriksen EF (1994) Effects of fluoride on human bone cells in vitro: differences in responsiveness between stromal osteoblast precursors and mature osteoblasts. Eur J Endocrinol 130:381–386PubMed
6.
Zurück zum Zitat Khokher MA, Dandona P (1990) Fluoride stimulates 2H-thymidine incorporation and alkaline phosphatase production by human osteoblasts. Metabolism 39:1118–1121PubMedCrossRef Khokher MA, Dandona P (1990) Fluoride stimulates 2H-thymidine incorporation and alkaline phosphatase production by human osteoblasts. Metabolism 39:1118–1121PubMedCrossRef
7.
Zurück zum Zitat Eriksen EF, Mosekilde L, Melsen F (1985) Effect of sodium fluoride, calcium, phosphate and vitamin D2 on trabecular bone balance and remodeling in osteoporotics. Bone 6:381–389PubMedCrossRef Eriksen EF, Mosekilde L, Melsen F (1985) Effect of sodium fluoride, calcium, phosphate and vitamin D2 on trabecular bone balance and remodeling in osteoporotics. Bone 6:381–389PubMedCrossRef
8.
Zurück zum Zitat Charles P, Mosekilde L, Jensen FT (1985) The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. Bone 6:201–206PubMedCrossRef Charles P, Mosekilde L, Jensen FT (1985) The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. Bone 6:201–206PubMedCrossRef
9.
Zurück zum Zitat Briancon D, Meunier PJ (1981) Treatment of osteoporosis with fluoride, calcium, and vitamin D. Orthop Clin North Am 12:629–648PubMed Briancon D, Meunier PJ (1981) Treatment of osteoporosis with fluoride, calcium, and vitamin D. Orthop Clin North Am 12:629–648PubMed
10.
Zurück zum Zitat Vesterby A, Gundersen HJG, Melsen F, Mosekilde L (1991) Marrow space star volume in iliac crest decreases in osteoporotic patients after continuous treatment with fluoride, calcium and vitamin. Bone 12:33–37PubMedCrossRef Vesterby A, Gundersen HJG, Melsen F, Mosekilde L (1991) Marrow space star volume in iliac crest decreases in osteoporotic patients after continuous treatment with fluoride, calcium and vitamin. Bone 12:33–37PubMedCrossRef
11.
Zurück zum Zitat Melsen F, Eriksen EF, Mosekilde L (1996) Clinical aspects of fluoride in bone. In: Fejerskov O, Ekstrand J, Burt BA (eds) Fluoride in dentristy, 1st edn. Munksgaard,Copenhagen, pp 96–111 Melsen F, Eriksen EF, Mosekilde L (1996) Clinical aspects of fluoride in bone. In: Fejerskov O, Ekstrand J, Burt BA (eds) Fluoride in dentristy, 1st edn. Munksgaard,Copenhagen, pp 96–111
12.
Zurück zum Zitat Sogaard CH, Mosekilde L, Richards A, Mosekilde L (1994) Marked decrease in trabecular bone quality after five years of sodium fluoride therapy - assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone 15:393–399PubMedCrossRef Sogaard CH, Mosekilde L, Richards A, Mosekilde L (1994) Marked decrease in trabecular bone quality after five years of sodium fluoride therapy - assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone 15:393–399PubMedCrossRef
13.
Zurück zum Zitat Schnitzler CM, Solomon L (1985) Trabecular stress fractures during fluoride therapy for osteoporosis. Skeletal Radiol 14:276–279PubMedCrossRef Schnitzler CM, Solomon L (1985) Trabecular stress fractures during fluoride therapy for osteoporosis. Skeletal Radiol 14:276–279PubMedCrossRef
14.
Zurück zum Zitat Haguenauer D, Welch V, Shea B, Tugwell P, Wells G (2000) Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD002825 Haguenauer D, Welch V, Shea B, Tugwell P, Wells G (2000) Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD002825
15.
Zurück zum Zitat Riggs BL, Seeman E, Hodgson SF, Taves DR, O’Fallon WM (1982) Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med 306:446–450PubMedCrossRef Riggs BL, Seeman E, Hodgson SF, Taves DR, O’Fallon WM (1982) Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med 306:446–450PubMedCrossRef
16.
Zurück zum Zitat Grove O, Halver B (1981) Relief of osteoporotic backache with fluoride, calcium, and calciferol. Acta Med Scand 209:469–471PubMedCrossRef Grove O, Halver B (1981) Relief of osteoporotic backache with fluoride, calcium, and calciferol. Acta Med Scand 209:469–471PubMedCrossRef
17.
Zurück zum Zitat Christiansen C, Christensen MS, McNair P et al (1980) Prevention of early bone postmenopausal loss: controlled 2-year study in 315 normal females. European J Clin Invest 10:273–279CrossRef Christiansen C, Christensen MS, McNair P et al (1980) Prevention of early bone postmenopausal loss: controlled 2-year study in 315 normal females. European J Clin Invest 10:273–279CrossRef
18.
Zurück zum Zitat Böhning D (2000) Computer-assisted analysis of mixtures and applications: meta-analysis, disease mapping and others, 1st edn. Chapman&Hall/CRC, Boca Raton Böhning D (2000) Computer-assisted analysis of mixtures and applications: meta-analysis, disease mapping and others, 1st edn. Chapman&Hall/CRC, Boca Raton
19.
Zurück zum Zitat Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691PubMedCrossRef Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691PubMedCrossRef
20.
Zurück zum Zitat Knapp G, Hartung J (2003) Improved tests for a random effects meta-regression with a single covariate. Stat Med 22:2693–2710PubMedCrossRef Knapp G, Hartung J (2003) Improved tests for a random effects meta-regression with a single covariate. Stat Med 22:2693–2710PubMedCrossRef
21.
Zurück zum Zitat Siddiqi A, Burrin JM, Noonan K et al (1997) A longitudinal study of markers of bone turnover in Graves’ disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 82:753–759PubMedCrossRef Siddiqi A, Burrin JM, Noonan K et al (1997) A longitudinal study of markers of bone turnover in Graves’ disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 82:753–759PubMedCrossRef
22.
Zurück zum Zitat Jowsey J, Riggs BL, Kelly PJ, Hoffman DL (1972) Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med 53:43–49PubMedCrossRef Jowsey J, Riggs BL, Kelly PJ, Hoffman DL (1972) Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med 53:43–49PubMedCrossRef
23.
Zurück zum Zitat Riggs BL, Hodgson SF, O’Fallon WM et al (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809PubMedCrossRef Riggs BL, Hodgson SF, O’Fallon WM et al (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809PubMedCrossRef
24.
Zurück zum Zitat Orcel P, De Vernejoul MC, Prier A et al (1990) Stress fractures of lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res 5:S91–S94CrossRef Orcel P, De Vernejoul MC, Prier A et al (1990) Stress fractures of lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res 5:S91–S94CrossRef
25.
Zurück zum Zitat Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P (2007) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int 18:45—57PubMedCrossRef Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P (2007) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int 18:45—57PubMedCrossRef
26.
Zurück zum Zitat O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD005326 O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD005326
27.
Zurück zum Zitat Abitbol V, Mary JY, Roux C et al (2002) Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 16:919—927PubMedCrossRef Abitbol V, Mary JY, Roux C et al (2002) Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 16:919—927PubMedCrossRef
28.
Zurück zum Zitat Adachi JD, Bell MJ, Bensen WG et al (1997) Fluoride therapy in prevention of rheumatoid arthritis induced bone loss. J Rheumatol 24:2308—2313PubMed Adachi JD, Bell MJ, Bensen WG et al (1997) Fluoride therapy in prevention of rheumatoid arthritis induced bone loss. J Rheumatol 24:2308—2313PubMed
29.
Zurück zum Zitat Adachi JD, Bell MJ, Bensen WG, et al (1996) A randomized, double-blind, placebo-controlled trial of the effects of fluoride on lumbar spine bone mineral density in patients with rheumatoid arthritis. Arthritis Rheum 39:661 Adachi JD, Bell MJ, Bensen WG, et al (1996) A randomized, double-blind, placebo-controlled trial of the effects of fluoride on lumbar spine bone mineral density in patients with rheumatoid arthritis. Arthritis Rheum 39:661
30.
Zurück zum Zitat Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 84:3013–3020PubMedCrossRef Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 84:3013–3020PubMedCrossRef
31.
Zurück zum Zitat Gambacciani M, Spinetti A, Taponeco F et al (1995) Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study. Osteoporos Int 5:467–471PubMedCrossRef Gambacciani M, Spinetti A, Taponeco F et al (1995) Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study. Osteoporos Int 5:467–471PubMedCrossRef
32.
Zurück zum Zitat Guanabens N, Pares A, Monegal A et al (1997) Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 113:219–224PubMedCrossRef Guanabens N, Pares A, Monegal A et al (1997) Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 113:219–224PubMedCrossRef
33.
Zurück zum Zitat Guanabens N, Farrerons J, Perez-Edo L et al (2000) Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone 27:123–128PubMedCrossRef Guanabens N, Farrerons J, Perez-Edo L et al (2000) Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone 27:123–128PubMedCrossRef
34.
Zurück zum Zitat Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G (1996) In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int 6:171–177PubMedCrossRef Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G (1996) In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int 6:171–177PubMedCrossRef
35.
Zurück zum Zitat Gutteridge DH, Stewart GO, Prince RL et al (2002) A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 13:158–170PubMedCrossRef Gutteridge DH, Stewart GO, Prince RL et al (2002) A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 13:158–170PubMedCrossRef
36.
Zurück zum Zitat Hansson T, Roos B (1987) The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 40:315–317PubMedCrossRef Hansson T, Roos B (1987) The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 40:315–317PubMedCrossRef
37.
Zurück zum Zitat Kleerekoper M, Peterson EL, Nelson DA et al (1991) A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1:155–161PubMedCrossRef Kleerekoper M, Peterson EL, Nelson DA et al (1991) A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1:155–161PubMedCrossRef
38.
Zurück zum Zitat Lems WF, Jacobs JW, Bijlsma JW et al (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 56:357–363PubMed Lems WF, Jacobs JW, Bijlsma JW et al (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 56:357–363PubMed
39.
Zurück zum Zitat Lems WF, Jacobs WG, Bijlsma JW et al (1997) Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 7:575–582PubMedCrossRef Lems WF, Jacobs WG, Bijlsma JW et al (1997) Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 7:575–582PubMedCrossRef
40.
Zurück zum Zitat Lippuner K, Haller B, Casez JP, Montandon A, Jaeger P (1996) Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 22:207–213PubMed Lippuner K, Haller B, Casez JP, Montandon A, Jaeger P (1996) Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 22:207–213PubMed
41.
Zurück zum Zitat Mamelle N, Dusan R, Martin JL et al (1988) Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361–365PubMedCrossRef Mamelle N, Dusan R, Martin JL et al (1988) Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361–365PubMedCrossRef
42.
Zurück zum Zitat Meunier PJ, Sebert JL, Reginster JY et al (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 8:4–12PubMedCrossRef Meunier PJ, Sebert JL, Reginster JY et al (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 8:4–12PubMedCrossRef
43.
Zurück zum Zitat Pak CY, Sakhaee K, Adams-Huet B et al (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401–408PubMed Pak CY, Sakhaee K, Adams-Huet B et al (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401–408PubMed
44.
Zurück zum Zitat Reginster JY, Meurmans L, Zegels B et al (1998) The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 129:1–8PubMed Reginster JY, Meurmans L, Zegels B et al (1998) The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 129:1–8PubMed
45.
Zurück zum Zitat Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I (1998) Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int 8:47–52PubMedCrossRef Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I (1998) Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int 8:47–52PubMedCrossRef
46.
Zurück zum Zitat Ringe JD, Kipshoven C, Coster A, Umbach R (1999) Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 9:171–178PubMedCrossRef Ringe JD, Kipshoven C, Coster A, Umbach R (1999) Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 9:171–178PubMedCrossRef
47.
Zurück zum Zitat Ringe JD, Dorst A, Faber H et al (2005) Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int 25:296–300PubMedCrossRef Ringe JD, Dorst A, Faber H et al (2005) Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int 25:296–300PubMedCrossRef
48.
Zurück zum Zitat Sebert JL, Richard P, Mennecier I, Bisset JP, Loeb G (1995) Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Osteoporos Int 5:108–114PubMedCrossRef Sebert JL, Richard P, Mennecier I, Bisset JP, Loeb G (1995) Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Osteoporos Int 5:108–114PubMedCrossRef
49.
Zurück zum Zitat Von Tirpitz C, Klaus J, Bruckel J et al (2000) Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 12:19–24CrossRef Von Tirpitz C, Klaus J, Bruckel J et al (2000) Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 12:19–24CrossRef
50.
Zurück zum Zitat Von Tirpitz C, Klaus J, Steinkamp M et al (2003) Therapy of osteoporosis in patients with Crohn’s disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 17:807–816CrossRef Von Tirpitz C, Klaus J, Steinkamp M et al (2003) Therapy of osteoporosis in patients with Crohn’s disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 17:807–816CrossRef
51.
Zurück zum Zitat Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef
Metadaten
Titel
Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis
verfasst von
P. Vestergaard
N. R. Jorgensen
P. Schwarz
L. Mosekilde
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 3/2008
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-007-0437-6

Weitere Artikel der Ausgabe 3/2008

Osteoporosis International 3/2008 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.